Protein Kinase CK2 Cellular Function in Normal and Disease States (eBook)

Dr. Khalil Ahmed is a Professor at the University of Minnesota, and a Senior Research Career Scientist at Minneapolis VA Health Care System, Minneapolis, Minnesota, U.S.A. He has a long history of studies on the functional biology of protein kinase CK2 in normal and neoplastic cells. He originally described the signal mediated dynamic shuttling of CK2 in the cell, and discovered the role of CK2 as a suppressor of apoptosis. His current research is focused on the mechanism of CK2 regulation of cell death. He is also studying the development of molecular therapeutic strategies using a nanomedicine approach for treatment of prostate and other cancers. Dr. Olaf-Georg Issinger is a Professor at the University of Southern Denmark, Odense, Denmark. He has been involved in the initial cloning and characterization of protein kinase CK2, a prerequisite for the elucidation of its structure in the absence and presence of specific interaction molecules. His current research focuses on the exploration of cellular signaling pathways in cell lines with respect to the role of various protein kinases using newly characterized kinase inhibitors identified by screening small chemical compound libraries.Dr. Ryszard Szyszka is a Professor at the John Paul II Catholic University of Lublin, Poland. He is head of the Department of Molecular Biology and Dean of the Faculty of Biotechnology and Environmental Sciences. His research is focused on the identification and characterization of new substrates of protein kinase CK2 from Saccharomyces cerevisiae. Further areas of interest include the structure and regulation of yeast CK2, and discovery of novel CK2 inhibitors. 

Part I: Regulation and Structure-Function Studies of CK2

1. Yeast Asf1 protein as modulator of protein kinase CK2 activity
Andrea Baier, Ewa Alikowska and Ryszard Szyszka

2. Impressions from the conformational and configurational space captured by protein kinase CK2
Jennifer Hochscherf, Alexander Schnitzler, Olaf-Georg Issinger and Karsten Niefind

3. Structural basis of CK2 regulation by autoinhibitory oligomerization
Graziano Lolli and Roberto Battistutta

4. Maize RNA binding protein ZmTGH: a new partner for CK2β1 regulatory subunit
Isabel Cristina Vélez-Bermúdez and Marta Riera

Part II: CK2 Control of Organismal and Cellular Functions

5. CK2 in Organ Development, Physiology, and Homeostasis
Charina E. Ortega, Lawrence Prince-Wright, and Isabel Dominguez

6. Protein kinase CK2, a window into the post-translational regulation of the E(spl)/HES repressors from invertebrates and vertebrates
Adam T. Majot, Tyler R. Sizemore, Mohna Bandyopadhyay, Lucas M. Jozwick and Ashok P. Bidwai

7. Tissue specific functions and regulation of protein kinase CK2
Sabrina Welker, Christina Servas, Meng Rui, Claudia Götz and Mathias Montenarh

8. CK2 function in the regulation of Akt pathway
Cristina Girardi and Maria Ruzzene

9. Cellular zinc signalling is triggered by CK2
Thirayost Nimmanon and Kathryn M. Taylor

10. CK2 – A global regulator of cell death
Janeen H. Trembley, Fatima Qaiser, Betsy T. Kren, Khalil Ahmed

11. Protein Kinase CK2: Systematic Relationships with Other Post-Translational Modifications
David W. Litchfield and Laszlo Gyenis

12. Role for protein kinase CK2 on cell proliferation: Assessing CK2 complex components in the nucleus during the cell cycle progression
Miwako Kato Homma, Takeshi Shibata, Toshiyuki Suzuki, Masato Ogura, Hiroko Kozuka-Hata, Masaaki Oyama, and Yoshimi Homma

13. “Genuine” casein kinase: the false sister of CK2 that phosphorylates secreted proteins at S-x-E/pS motifs
Elena Tibaldi, Giorgio Arrigoni, Giorgio Cozza, Luca Cesaro, Lorenzo A. Pinna


Part III: Function of CK2 in Cancer and its Therapeutic Targeting

14. Dysregulated expression of Protein kinase CK2 in Renal cancer
Caroline Roelants, Sofia Giacosa, Eve Duchemin-Pelletier, Anne McLeer-Florin, Céline Tisseyre, Cédric Aubert, Pierre Champelovier, Jean Boutonnat, Jean Luc Descotes, Jean-Jacques Rambeaud, Valentin Arnoux, Jean-Alexandre Long, Dominique Pasquier, Mathieu Laramas, Maysoun Kassem, Laurence David-Boudet, Laure Schoutteten, Benoit Bestgen, Catherine Pillet, Claude Cochet, Odile Filhol

15. Protein Kinase CK2 and Dysregulated Oncogenic Inflammatory Signaling Pathways
Etty N. Benveniste, G. Kenneth Gray and Braden C. McFarland

16. CIGB-300: A promising anti-Casein Kinase 2 (CK2) peptide for cancer targeted therapy
Silvio E. Perea, Yasser Perera, Idania Baladrón, Lidia González, Fernando Benavent, Hernán G. Fariña, Idrián García, Arielis Rodríguez, Vilcy Reyes, Yanelda García, Roberto Gómez, Daniel F. Alonso, Carmen Valenzuela

17. Targeting CK2 for Cancer Therapy Using a Nanomedicine Approach
Khalil Ahmed, Gretchen Unger, Betsy T. Kren, Janeen H. Trembley


Part IV: Studies Involving CK2 Small Molecule Inhibitors

18. Screening of DTP compound libraries for CK2 inhibitors with focus on natural products
Tine D. Rasmussen, Barbara Guerra and Olaf-Georg Issinger

19. CK2 inhibitors and the DYRK family protein kinases
Yoshihiko Miyata

20. Sensitivity of protein kinase CK2 to ATP/GTP and specific inhibitors depends on complexity of interacting proteins
Andrea Baier and Ryszard Szyszka